Dr Datsons Labs has successfully completed its obligations towards FCCB bondholders for $40 million. Accordingly, there is no unpaid debt by the Company towards bondholders as on July 17, 2014.
Dr. Datsons Labs is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.